References
- 1. N. Y. Hasan, M. A. Elkawy, B. E. Elzeany and N. E. Wagieh, Stability indicating methods for the determination of clozapine, J. Pharm. Biomed. Anal. 30 (2002) 35-47; DOI: 10.1016/S0731-7085(02) 00125-5.
- 2. M. Ackenheil, Clozapine pharmacokinetic investigations and biochemical effects in man, Psychopharmacology 99 (1989) 32-37; DOI: 10.1007/bf00442556.10.1007/BF004425562682731
- 3. A. A. Ambike, K. Mahadik and A. Paradkar, Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations, Pharm. Res. 22 (2005) 990-998; DOI: 10.1007/ s11095-005-4594-z.
- 4. M. Kluge, A. Schuld, A. Schacht, H. Himmerich, M. A. Dalal, P. M. Wehmeier, D. Hinze-Selch, T. Kraus, R. W. Dittmann and T. Pollmcher, Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever, Psychoneuroendocrinology 34 (2009) 118-128; DOI: 10.1016/j.psyneuen.2008.08.016.10.1016/j.psyneuen.2008.08.01618835660
- 5. D. Douroumis, Orally disintegrating dosage forms and taste-masking technologies, Expert Opin. Drug Delivery. 8 (2010) 665-675; DOI: 10.1517/17425247.2011.566553.10.1517/17425247.2011.56655321438776
- 6. V. Venkateswarlu and K. Manjunath, Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles, J. Control. Release 95 (2004) 627-638; DOI: 10.1016/j.jconrel. 2004.01.005.
- 7. S. A. Agnihotri and T. M. Aminabhavi, Controlled release of clozapine through chitosan microparticles prepared by a novel method, J. Control. Release 96 (2004) 245-259; DOI: 10.1016/j.jconrel. 2004.01.025.
- 8. T. Vasconcelos, B. Sarmento and P. Costa, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, Drug Discov. Today 12 (2007) 1068-1075; DOI: 10.1016/j. drudis.2007.09.005.
- 9. O. Almarsson and M. J. Zaworotko, Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?, Chem. Commun. 17 (2004) 1889-1896; DOI: 10.1039/B402150A.10.1039/b402150a15340589
- 10. K. K. Arora and M. J. Zaworotko, Pharmaceutical co-crystals: A new Opportunity In Pharmaceutical Science for a Long-known but Little Studied Class of Compounds, in Polymorphism in Pharmaceutical Solids (Ed. H. G. Brittain), 2nd ed., Informa Healthcare, London 2009, pp. 281-313.
- 11. K. J. Crowley and G. Zografi, Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability, J. Pharm. Sci. 91 (2002) 492-507; DOI: 10.1002/jps.10028.10.1002/jps.1002811835208
- 12. E. Gagniere, D. Mangin, S. Veesler and F. Puel, Co-crystallization in Solution and Scale Up Issues, in Pharmaceutical Salts and Co-crystals (Eds. J. Wouters, L. Quere and D. E. Thurston), 1st ed., Royal Society of Chemistry, London 2011, pp. 188-208.10.1039/9781849733502-00188
- 13. N. Blagden, M. de Matas, P. T. Gavan and P. York, Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Adv. Drug Deliv. Rev. 59 (2007) 617-630; DOI: 10.1016/j.addr.2007.05.011.10.1016/j.addr.2007.05.01117597252
- 14. K. Lobmann, H. Grohganz, R. Laitinen, C. Strachan and T. Rades, Amino acids as co-amorphous stabilizers for poorly water soluble drugs-Part 1: Preparation, stability and dissolution enhancement, Eur. J. Pharm. Biopharm. 85 (2013) 873-881; DOI: 10.1016/j.ejpb.2013.03.014.10.1016/j.ejpb.2013.03.01423537574
- 15. Y. Gao, J. Liao, X. Qi and J. Zhang, Coamorphous repaglinide-saccharin with enhanced dissolution, Int. J. Pharm. 450 (2013) 290-295; DOI: 10.1016/j.ij pharm.2013.04.032.
- 16. A. Shayanfar, H. Ghavimi, H. Hamishekar and A. Jouyban, Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties, J. Pharm. Sci. 16 (2013) 577-587.
- 17. A. Lemmerer, J. Bernstein, and V. Kahlenberg, Hydrogen bonding patterns of the co-crystal containing the pharmaceutically active ingredient isoniazid and terephthalic acid, J. Chem. Crystallogr. 41 (2011) 991-997; DOI: 10.1007/s10870-011-0031-9.10.1007/s10870-011-0031-9
- 18. M. A. Elbagerma, H. G. M. Edwards, T. Munshi and I. J. Scowen, Identification of a new co-crystal of salicylic acid and benzamide of pharmaceutical relevance, Anal. Bioanal. Chem. 397 (2010) 137-146; DOI: 10.1007/s00216-009-3375-7.10.1007/s00216-009-3375-720039022
- 19. B. C. Hancock and M. Parks, What is the true solubility advantage for amorphous pharmaceuticals?, Pharm. Res. 17 (2000) 397-404; DOI: 10.1023/a:1007516718048.10.1023/A:1007516718048
- 20. S. U. Schilling, C. D. Bruce, N. H. Shah, A.W. Malick and J. W. McGinity, Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets, Int. J. Pharm. 361 (2008) 158-168; DOI: 10.1016/j.ij pharm.2008.05.035.
- 21. D. R. Weyna, T. Shattock, P. Vishweshwar and M. J. Zaworotko, Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanochemistry vs slow evaporation from solution, Cryst. Growth Des. 9 (2009) 1106-1123; DOI: 10.1021/cg800936d.10.1021/cg800936d
- 22. A. Newman, D. Engers, S. Bates, I. Ivanisevic, R. C. Kelly and G. Zografi, Characterization of amorphous API: Polymer mixtures using X-ray powder diffraction, J. Pharm. Sci. 97 (2008) 4840-4856; DOI: 10.1002/jps.21352.10.1002/jps.2135218351626
- 23. C. Guitton, J. M. Kinowski, R. Aznar and F. O. Bressolle, Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with ultraviolet absorbance detection, J. Chromatogr. 690 (1997) 211-222; DOI: 10.1016/s0378-4347 (96)00362-3.
- 24. M. Vasanthavada, W-Q. T. Tong, Y. Joshi and M. S. Kislalioglu, Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics, Pharm. Res. 22 (2005) 440-448; DOI: 10.1007/s11095-004-1882-y.10.1007/s11095-004-1882-y15835750
- 25. Q. Lu and G. Zografi, Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid and PVP, Pharm. Res. 15 (1998) 1202-1206; DOI: 10.1023/a:1011983606606.10.1023/A:1011983606606
- 26. H. Bley, B. Fussnegger and R. Bodmeier, Characterization and stability of solid dispersions based on PEG/polymer blends, Int. J. Pharm. 390 (2010) 165-173; DOI: 10.1016/j.ij pharm.2010.01.039.
- 27. J. E. Patterson, M. B. James, A. H. Forster, R.W. Lancaster, J. M. Butler and T. Rades, Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling, Int. J. Pharm. 336 (2007) 22-34; DOI: 10.1016/j.ij pharm.2006.11.030.